Johnson & Johnson Net Income/Loss 2010-2024 | JNJ

Johnson & Johnson annual/quarterly net income/loss history and growth rate from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
  • Johnson & Johnson net income/loss for the quarter ending September 30, 2024 was $10.635B, a 65.81% decline year-over-year.
  • Johnson & Johnson net income/loss for the twelve months ending September 30, 2024 was $56.984B, a 5.42% increase year-over-year.
  • Johnson & Johnson annual net income/loss for 2023 was $35.153B, a 95.94% increase from 2022.
  • Johnson & Johnson annual net income/loss for 2022 was $17.941B, a 14.07% decline from 2021.
  • Johnson & Johnson annual net income/loss for 2021 was $20.878B, a 41.89% increase from 2020.
Johnson & Johnson Annual Net Income/Loss
(Millions of US $)
2023 $35,153
2022 $17,941
2021 $20,878
2020 $14,714
2019 $15,119
2018 $15,297
2017 $1,300
2016 $16,540
2015 $15,409
2014 $16,323
2013 $13,831
2012 $10,514
2011 $9,672
2010 $13,334
2009 $12,266
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $347.829B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $728.847B 75.49
Novo Nordisk (NVO) Denmark $381.440B 27.51
AbbVie (ABBV) United States $310.275B 16.33
Merck (MRK) United States $248.031B 16.48
AstraZeneca (AZN) United Kingdom $202.626B 17.24
Novartis AG (NVS) Switzerland $198.493B 13.19
Pfizer (PFE) United States $149.382B 10.22
Sanofi (SNY) $121.080B 10.97
Bayer (BAYRY) Germany $19.295B 3.09
Innoviva (INVA) United States $1.117B 9.29